Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Cerecor (CERC) Competitors

Cerecor logo

CERC vs. GMTX, CALT, ZYME, MENS, SBTX, MBX, AVTE, NLTX, CYBN, and BIOA

Should you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), and BioAge Labs (BIOA).

Cerecor vs. Its Competitors

Cerecor (NASDAQ:CERC) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Cerecor has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Cerecor, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerecor$6.70M95.87-$63.50M-$0.57-11.74
Gemini TherapeuticsN/AN/A-$71.87M-$1.00-60.58

62.8% of Cerecor shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 45.7% of Cerecor shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cerecor has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500.

In the previous week, Cerecor's average media sentiment score of 0.16 beat Gemini Therapeutics' score of 0.00 indicating that Cerecor is being referred to more favorably in the media.

Company Overall Sentiment
Cerecor Neutral
Gemini Therapeutics Neutral

Gemini Therapeutics has a net margin of 0.00% compared to Cerecor's net margin of -1,194.82%. Gemini Therapeutics' return on equity of -38.78% beat Cerecor's return on equity.

Company Net Margins Return on Equity Return on Assets
Cerecor-1,194.82% -261.82% -133.96%
Gemini Therapeutics N/A -38.78%-35.88%

Summary

Cerecor beats Gemini Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Cerecor News Delivered to You Automatically

Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CERC vs. The Competition

MetricCerecorPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$642.30M$776.92M$5.70B$9.50B
Dividend YieldN/A4.84%4.60%4.01%
P/E Ratio-11.741.4028.1020.05
Price / Sales95.8725.35429.3789.38
Price / CashN/A19.5636.2258.56
Price / Book30.416.798.665.87
Net Income-$63.50M-$4.32M$3.25B$258.55M

Cerecor Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CERC
Cerecor
N/A$6.69
+0.9%
N/A-43.4%$642.30M$6.70M-11.7431
GMTX
Gemini Therapeutics
N/A$59.38
+2.8%
N/A+36.0%$2.57BN/A-59.3830High Trading Volume
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
ZYME
Zymeworks
2.5026 of 5 stars
$14.32
flat
$21.00
+46.6%
+25.4%$997.86M$93.38M-9.55460Upcoming Earnings
MENS
Jyong Biotech
N/A$10.06
-8.5%
N/AN/A$764.84MN/A0.0031Quiet Period Expiration
SBTX
Silverback Therapeutics
N/A$17.85
-0.4%
N/A+60.1%$643.64MN/A-7.3883High Trading Volume
MBX
MBX Biosciences
2.1297 of 5 stars
$11.70
-4.0%
$37.57
+221.1%
N/A$391.06MN/A0.0036News Coverage
AVTE
Aerovate Therapeutics
N/A$8.69
-8.2%
N/A-87.6%$251.88MN/A-2.9120High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$22.34
-1.2%
N/A-46.6%$209.95MN/A-7.1890High Trading Volume
CYBN
Cybin
2.7149 of 5 stars
$7.73
-3.7%
$85.00
+999.6%
N/A$177.98MN/A-1.7650
BIOA
BioAge Labs
N/A$4.76
+3.5%
N/AN/A$170.65M$1.45M0.00N/A

Related Companies and Tools


This page (NASDAQ:CERC) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners